Abstract
Diseases of the bile duct (cholangiopathies) remain a common indication for liver transplantation, while little progress has been made over the last decade in understanding the underlying pathophysiology. This is largely due to lack of proper in vitro model systems to study cholangiopathies. Recently, a culture method has been developed that allows for expansion of human bile duct epithelial cells grown as extrahepatic cholangiocyte organoids (ncECOs) in non-canonical Wnt-stimulating conditions. These ncECOs closely resemble cholangiocytes in culture and have shown to efficiently repopulate collagen scaffolds that could act as functional biliary tissue in mice. Thus far, initiation of ncECOs required tissue samples, thereby limiting broad patient-specific applications. Here, we report that bile fluid, which can be less invasively obtained and with low risk for the patients, is an alternative source for culturing ncECOs. Further characterization showed that bile-derived cholangiocyte organoids (ncBCOs) are highly similar to ncECOs obtained from bile duct tissue biopsies. Compared to the previously reported bile-cholangiocyte organoids cultured in canonical Wnt-stimulation conditions, ncBCOs have superior function of cholangiocyte ion channels and are able to respond to secretin and somatostatin. In conclusion, bile is a new, less invasive, source for patient-derived cholangiocyte organoids and makes their regenerative medicine applications more safe and feasible.
Introduction
Cholangiopathies are associated with significant morbidity and mortality (; ). Insight in the underlying pathophysiology and treatment options is incomplete, mostly due to the lack of good model systems to culture and expand primary human cholangiocytes (). Recently, described a method to expand primary human cholangiocytes from extrahepatic bile duct biopsies and culture them as three-dimensional (3D) organoids. These so-called extrahepatic cholangiocyte organoids (ncECOs) retained most biliary characteristics in culture and were successfully used to bioengineer artificial ducts that, after transplantation in mice, act as functional bile ducts. The culture of ncECOs is driven by non-canonical Wnt-signaling (ncECOs) stimulated by R-spondin in combination with Dickkopf-related protein-1 (DKK-1). Also in vivo, non-canonical Wnt-stimulation is important for cholangiocyte homeostasis and proliferation responses to bile duct injury (; ). Although highly effective, to grow these organoids either a tissue biopsy from the gallbladder or a brush via an endoscopic retrograde cholangiopancreatography (ERCP) is needed (; ). These options are potentially harmful to patients () or are procedures not regularly performed. This limits broad patient-specific disease modeling and regenerative medicine applications. To avoid the need for tissue-derived samples, we explored the use of human bile as an alternative, less invasive, source for patient-derived ncECOs. A recent study published by showed feasibility of culturing cholangiocyte organoids from bile, obtained by ERCP. The expansion of these bile-derived organoids were driven by canonical Wnt-signaling originally described for the growing intrahepatic cholangiocyte organoids (cICOs) (). This canonical Wnt-signaling is stimulated by R-spondin, providing a cholangiocyte with a more stem cell-like phenotype compared to in vivo cholangiocytes (, ; ; ; ). Moreover, these canonical Wnt stimulation culture conditions will likely result in a different cell phenotype than observed under non-canonical Wnt conditions (). Since bile duct tissue-derived ECOs cultured in canonical-Wnt conditions (cECOs) do upregulate Wnt-target genes, while ncECOs do not (; ). Currently, it is unknown whether under non-canonical Wnt-stimulated conditions cholangiocyte organoids can be expanded from bile and retain a more cholangiocyte-like phenotype. Therefore, the aim of this study is to initiate and expand non-canonical Wnt driven cholangiocyte organoids from bile (ncBCOs) and to compare these to canonical-Wnt driven bile cholangiocyte organoids (cBCOs) from the same bile samples and to ncECOs from (paired) bile duct tissue.
Materials and Methods
Bile and Tissue Collection
Fresh bile (1 ml) was collected from patients receiving an ERCP (n = 8) for their regular treatment (complete list of patients see Supplementary Table 1). In addition, bile (3 ml) was collected ex vivo from gallbladders after surgical removal (n = 8). Bile from gallbladders was collected from donor livers allocated for liver transplantation (n = 8). Additionally, tissue samples were collected from gall bladders (n = 5), either collected after cholecystectomy (n = 1) at the IJsselland Hospital, Capelle aan de IJssel, Netherlands, or were along with liver biopsies (n = 3) or extrahepatic bile duct (EHBD, n = 4) biopsies, collected from gall bladders from donor livers allocated for liver transplantation (n = 4). All bile samples were stored immediately on ice and were processed as soon as possible after collection. All patients or their next of kin consented with the use of their bile or tissue for research purposes by signing an informed consent, and the use of this material was approved by the Medical Ethical Committee of the Erasmus MC, Rotterdam (MEC-2014-060, MEC-2016-743, and MEC 2018-1174).
Generation and Culture of Canonical and Non-canonical Wnt Stimulated Cholangiocyte Organoids From Bile and Tissue
For the initiation (of culture) of canonical Wnt stimulated bile or intrahepatic or extrahepatic bile duct tissue cholangiocyte organoids (cBCOs, cICOs, and cECOs, respectively), and non-canonical Wnt stimulated extrahepatic bile duct tissue (ncECOs), we used protocols similar to the ones previously published (; ; ; ; ). For detailed methodology, please refer to Supplementary Material and Methods. Human ncBCOs (n = 16) were cultured from 1 ml (ERCP) or 3 ml of bile (gallbladder), depending on the source. Bile was centrifuged at 453 g for 5 min at 4°C, supernatant was removed, and the cell pellet was washed twice with excess cold William’s-E medium (WE). Finally, the pellet was suspended in WE and filtered through a 70-μm cell strainer to remove debris. Afterward, cells were plated out in a 25-μl droplets of basement membrane extract (BME, Cultrex) and culture medium (WE with supplements) was added according to the standard ncECO protocol (; ). Medium was changed twice a week, and cultures were split in a 1:2 to 1:10 ratio depending on the number and size of organoids grown. Cultures were routinely checked for mycoplasma contamination, which came back negative. All experiments with ncECOs and ncBCOs were performed with passage five or higher, unless stated otherwise. For a complete overview of the nomenclature and culture conditions for cholangiocyte organoids and patient characteristics, see Supplementary Tables 1, 3.
Flow-Cytometry of Bile-Derived Cells and ncBCOs
Fresh human bile was obtained from patients immediately after collection via ERCP (n = 3) and stored at 4°C during transportation. Bile was transferred to a 15 mL Falcon tube and centrifuged for 5 min at 4°C, supernatant was removed, and the cell pellet was washed twice with WE. ncBCOs were made single cell by incubation with Trypsin-EDTA (TE) for 25 to 40 min, at 37°C. Cells were washed in WE and put through a cell 70 μm cell strainer. Samples were blocked in 1% bovine serum albumin (BSA)-Phosphate-buffered saline (PBS) for 15 min. TROP2 antibody (Invitrogen; rabbit monoclonal conjugated to Alexa Fluor-488, clone MR54, used 1:100) was added (30 min, on ice), and cells were subsequently measured on a Canto flow cytometer (BD Biosciences).
RNA Extraction, cDNA Synthesis, and RT-qPCR
RNA was harvested by the addition of 700 μl of QIAzol lysis reagent (Qiagen) per two 25-μl domes of ncECO (n = 6), ncBCO (n = 6), and cBCOs (n = 6). RNA extraction and subsequent cDNA synthesis was performed as previously published (). In short, RNA was isolated using an miRNeasy kit (Qiagen) according to the manufacturer’s protocol. RNA concentration was measured using a NANOdrop 2,000 (Thermo Fisher). cDNA (500 ng) was prepared using 5× PrimeScript RT Master Mix in a 2,720 thermal cycler (Applied Biosystems). RT-qPCR was performed with the primer sets provided in Supplementary Data Table 2. All RT-qPCR data are presented as mean with a 95% confidence interval. RT-qPCR values are relative to the housekeeping gene Hypoxanthine-guanine-fosforibosyl-transferase (HPRT) or Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and for visual interpretation multiplied by 105 or 106.
Immunohistochemistry
Immunohistochemistry (IHC) was performed according to standard procedures as previously described for cICOs; liver biopsies obtained from donors allocated for transplantation were taken along as control (). In short, formalin-fixed, paraffin-embedded bile duct biopsies were sectioned (4 μm thick) and processed according to standard procedures. Antigen retrieval was performed in citrate buffer (pH 6.0) for 10 min in sub boiling temperatures and non-specific reactions were blocked by incubation with 10% goat serum in a 1% BSA-PBS solution. The sections were exposed to primary antibodies overnight at 4°C Cytokeratin (KRT)19 and KRT7 antibodies (both Dako were used in 1:100 dilution in 1% BSA-PBS). The antibody for Cystic Fibrosis Transmembrane Conductance Regulator (CFTR, EMD Millipore Corp.) was used in a 1:200 dilution of 1% BSA-PBS. Sections were subsequently incubated with Envision + system horseradish peroxidase anti-mouse secondary antibody (Dako) at room temperature for 60 min, before staining with 3′-diaminobenzidine (DAB). Nuclei were stained by hematoxylin. Analysis was done with a Carl Zeiss Axioskop 20 microscope, and images were taken with a Nikon Digital Side DS-5M camera.
Gene-Array Selection-Based qRT-PCR
Twenty genes were selected from the online published Microarray gene expression data corresponding to the heat map (Figure 1D) published in . Out of the gene-expression heatmap, 10 genes were selected, which have a similar expression between primary human cholangiocytes and ncECOs, five genes were selected, which have higher expression in ncECOs compared with primary human cholangiocytes and five genes, which have lower expression in ncECOs compared with primary human cholangiocytes. Additionally, 15 genes known to be Wnt-target/stem cell-related or hepatocyte and cholangiocyte specific, were selected (), and their expression was assessed by RT-qPCR. The selected genes and correlating primer sets are listed in Supplementary Data Table 2. The details on the ncECOs and ncBCOs used are described in Supplementary Data Table 1. A Z-stack heat-map was created by unsupervised hierarchical clustering in R (version 3.5.1, R Core Team) supplemented with package Gplots (version 3.0.1).
FIGURE 1
Swelling of Cholangiocyte Organoids
To assess functionality of secretin and somatostatin, a slight modification of the Forskolin-Induced Swelling (FIS) assay as developed by was applied. For this, ncECOs and ncBCOs organoids were incubated for 30 min with 3 μM calcein-green (Invitrogen), stimulated with secretin (10 μM) or secretin and somatostatin (100 μM) and analyzed by confocal live cell microscopy at 37°C for 120 min (LSM710, Zeiss). The total or single organoid area (XY plane) increase relative to t = 0 of secretin treatment was quantified using velocity imaging software (Improvision) and compared to non-stimulated controls. Cell debris and unviable structures were manually excluded from image analysis.
Gamma-Glutamyltransferase Assay
Ten microliters of supernatant of cholangiocyte organoids from bile (ncBCOs, n = 3) and from tissue (ncECOs, n = 3) were collected. Next, Gamma-glutamyltransferase (GGT) activity colorimetric assay kit (MAK089; Sigma-Aldrich) was used according to the manufacturer’s protocol.
Rhodamine 123 Transport Assay
Functionality of the multi drug resistance-1 (MDR-1) transporter was performed according standard protocol using a commercially available Rhodamine 123 assay (Sigma Aldrich) (). Rhodamine 123 transport was determined by incubating the cultures with Rhodamine 123 (100 μM, Sigma Aldrich) for 5°min at 37°C. Subsequently, specificity of the MDR-1 transporter was determined by blocking the transporter with Verapamil (10°μM, Sigma Aldrich) for 30°min at 37°C prior to Rhodamine 123 incubation (100°μM, Sigma Aldrich). Confocal analysis was performed to determine MDR-1 activity. Images were acquired with a Leica SP5 confocal microscope (LEICA) equipped with a 488-nm laser.
Ussing Chamber Assay
Extrahepatic cholangiocyte organoids, ncBCOs, cICOs, and cBCOs (all n = 3) were collected from 10–25 μl domes. Organoids were collected in WE, centrifuged (453 g, 5 min, 4°C) and the supernatant was removed. Organoids were mechanically broken by pipetting up and down and were spun down again. A single cell suspension was made through incubation of the organoids in 1 ml TE for 25 to 40 min, at 37°C. Cells were washed in WE and put through a cell 70 μm cell strainer. Approximately, 3 × 105 cells were resuspended in 200 μm WE-medium with supplements () and seeded on Transwell inserts (24-well plate 6.5 mm, Corning). Medium was changed twice per week. To check confluency, electrophysiological analysis (TEER) was performed after 4 days. The confluent Transwells were placed in an Ussing chamber set up to analyze functional cholangiocyte-specific transporter channels (CFTR and Ca2+ dependent Cl– channel) using Acquire and Analyze Software 2.3 (Physiologic Instruments, San Diego, CA, United States). For detailed methodology of the conditions, please see Supplementary Material and Methods.
RNA Isolation for Microarray
Total RNA was isolated from cECOs using the miRNEAsy mini kit (Qiagen, Hilden, Germany) according to the manufacturer’s protocol and eluted in 30 μl of RNAse-free water. RNA concentration and integrity were determined using a Nanodrop 2000 (Thermo Fisher Scientific, Waltham MA, United States) and a Bioanalyzer 2,100 (Agilent Technologies, Santa Clara CA, United States), respectively. A total of 300 ng RNA was reversed transcribed, amplified, and biotin-labeled using the Illumina TotalPrep RNA Amplification Kit (Ambion-Life Technologies, Carlsbad CA, United States) according to the manufacturer’s guidelines. HumanHT-12 v4 Expression BeadChips (Illumina, San Diego CA, United States) were overnight hybridized with 750 ng cRNA, washed, stained, and scanned on an iScan and analyzed using GenomeStudio V2011.1 software (both from Illumina, Inc.).
Microarray Analysis
Microarray analysis was based upon the publically available data of ncECOs from ArrayExpress E-MTAB-4591 [, Nature Medine 2017, n = 3], cICOs (n = 3) from the ArrayExpress E-MTAB-9044 (Roos et al. unpublished), and the novel data generated for cECOs (deposited at Array Express, E-MTAB-9807). Bead types missing in one or more arrays were excluded, and the resulting non-normalized raw probe data set was combined with the open datasets. The file, describing for each probe AVG_Signal and Detection Pval, was loaded into R using the limma package (). limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Research 43, e47). Probes that were present at least once (Detection Pval <0.01) were considered as being expressed (21,929 probes) and used for further analysis. Following filtering, the data were background subtracted, normalized, and log2 transformed using the VSN package (Huber W, von Heydebreck A, Sueltmann H, Poustka A, Vingron M (2002). “Variance Stabilization Applied to Microarray Data Calibration and to the Quantification of Differential Expression.” Bioinformatics, 18 Suppl. 1, S96-S104). The heatmap was conducted in R using heatmap.2 functions.
Statistical Analysis
All analyses were conducted using SPSS software (statistical Product and Service solutions, version 22, SSPS Inc., Chicago, IL, United States), and graphs were performed using GraphPad Prism 7.0 (GraphPad Software Inc., United States). Continuous variables were tested using an independent T-test or Mann–Whitney-U test and presented with normal distribution as means with standard error of the mean and if not normally distributed, they are presented as range. Gene array unsupervised hierarchical clustering data was statistically analyzed using Pearson’s correlation was calculated between the eight samples (reference ncBCO 10). In all tests, a P-value of <0.05 was considered significant.
Results
Cholangiocyte Organoids in Non-canonical Wnt Stimulating Conditions Can Successfully Be Expanded From Human Bile
In Figure 1A, a schematic overview of the culture protocol for bile cholangiocyte organoids (ncBCOs) from bile is displayed. As shown in Figure 1B, ncBCOs could be successfully cultured from bile obtained from multiple organ donors or patients with different underlying liver or biliary diseases (n = 15). Donor, patient, and culture characteristics are shown in Supplementary Data Table 1. NcBCOs could be initiated from both ERCP- and gallbladder bile with a high success rate (15 from 16, 94%). Morphologically ncECOs and ncBCOs looked similar under bright-field microscopy (Figure 1B). Recent evidence showed that primary human cholangiocytes are Trop2 positive (). Thus, to investigate if primary cholangiocytes are present in bile we looked at Trop2pos cells. As shown in Figure 1C, the Trop2pos cell population was the highly dominated population within the bile samples (mean percentage 62.20 ± 2.69). To confirm that ncBCOs resemble their Trop2pos organoid-initiating population in vitro, we performed flow cytometry analysis on ncBCOs. As indicated by Figure 1C, almost all cells found within organoids are indeed Trop2pos (mean percentage 95.43 ± 0.67) highlighting their resemblances to primary cholangiocytes. Similar to ncECOs, ncBCOs rapidly expanded and could be passaged approximately one time a week in a 1:3 ratio. ncBCOs could be passaged for at least 15 passages (>3 months) (Figure 1D).
ncBCOs and ncECOs Have Similar Gene- and Protein-Expression Profiles
To determine the phenotype of ncBCOs, gene-expression of a selected number of cholangiocyte-specific genes was assessed and compared to ncECOs using qRT-PCR (). Organoid lines included for qRT-PCR analysis were almost all (four out of six) paired from the same donor to overcome donor variances. Additionally, samples were from patients with a similar disease (ncBCO8 and ncECO11), or with a relatively healthy bile duct (ncBCO10 and ncECO12). Details of the origin of the organoids are shown in Supplementary Table 1). Expression of cholangiocyte markers KRT19, KRT7, and hepatocyte nuclear factor-1beta (HNF1β), CFTR, Trefoil Factor 1 (TFF1), Trefoil Factor 2 (TFF2), and biliary progenitor marker sex-determining region Y (Sox)9 was assessed. As shown in Figure 2A, these cholangiocyte markers were highly expressed in ncECOs and ncBCOs and no significant differences in expression was observed. As a control, the expression of hepatocyte markers albumin (ALB) and CYP3A4 compared to liver-tissue biopsies, as well as the Wnt-target gene leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5) and the stem cell marker prominin-1, also known as CD133, was determined (Figure 2B). Compared to liver biopsies that mostly consists of hepatocytes, the expression of the hepatocyte markers albumin and Cyp3A4 was 17,500–114,970 times and 32–260 times lower in ncECOs and ncBCOs, respectively (Figure 2B), highlighting the resemblance of ncECOs and ncBCOs with cholangiocytes. Furthermore, no differences in gene-expression for LGR5 and CD133 could be determined between ncECOs and ncBCOs. To further confirm that ncBCOs have a similar gene expression profile as ncECOs, the expression of 35 genes (for gene selection see Material and Methods) was determined in ncBCOs and ncECOs using cluster analyses. Pearson correlation coefficient showed no major differences between the expression of these genes in both organoid types (Figure 2C). To confirm that the organoids are polarized, a CFTR-staining was performed, as shown in Figure 2D. CFTR is predominantly expressed on the luminal side of our ncBCOs, resembling the in vivo situation in the liver (Figure 2D). Furthermore, IHC staining of KRT7 and KRT19 confirmed expression of both cholangiocyte markers in the cytoplasm of ncBCO and ncECOs. Moreover, histology revealed a typical columnar-like epithelium in the organoids, with the nucleus located basolateral, similar to primary cholangiocytes in tissue biopsies (Figure 2E) ().
FIGURE 2
Both ncBCOs and ncECOs Have Cholangiocyte Functionality in vitro
Cholangiocytes influence bile quality by secretion of ions via either CaCl and Anoctamin-1 (ANO1) transporter channels or via an increase of cAMP, which regulates CFTR (
FIGURE 3

ncBCOs and ncECOs both have functional cholangiocyte activity. (A) Representative images of selected ncECOs and ncBCOs at time is 0 min, and time is 120 min of measurements in the secretin and unstimulated (unstimulated) groups. (B) Quantification of organoid swelling in ncECOs and ncBCOs in different groups, scale bars indicate 50 μm. (C) ncBCOs show clear multi drug resistance-1 (MDR-1) activity as Rhodamine 123 was actively transported out of the cells into the lumen of the organoid. Specificity was confirmed by inhibition with Verapamil. (D) Gamma-glutamyltransferase (GGT) activity (U/I) as measured by ELISA in both ncECOs and ncBCOs supernatants (n = 3), scale bars indicate 100 μm. (E) Representative ion-channel functionality of 2D-grown ncBCOs (line 1) and ncECOs (line 2) in an Ussing chamber. Stimulation with cAMP-activator, forskolin, resulted in an increase in short circuit current, demonstrating CFTR-mediated activity (Cystic Fibrosis Transmembrane conductance Regulator). This was completely blocked by CFTR-inhibitor, GlyH-101. Also, calcium-depended chloride excretion ion channel activity, specifically stimulated by UTP and inhibited by T16Ainh-A01, was identical between ncBCOs and ncECOs.
The capability to export drugs was confirmed in ncBCOs by imaging effective transport of Rhodamine 123 by the multidrug resistance protein-1 (MDR1) (
Previous work by
Organoids are normally grown in a 3D setting, making it difficult to access the cells’ luminal side. In cholangiocytes, both the ANO1 and CFTR channel are located at the luminal side. To overcome the hurdle of accessing this side, both ncBCOs and ncECOs were grown as 2D monolayers and ion-channel functionality was addressed in an Ussing chamber. As shown in Figure 3E, ncECOs and ncBCOs both responded to activation with forskolin (cAMP-activator), which was completely inhibited by addition of GlyH-101, a CFTR-inhibitor, to the luminal side. Additionally, stimulation by UTP (luminal) and inhibition (by T16Ainh-A01, luminal) demonstrated the presence of functional ANO1 in both organoid types. Combined, this demonstrates that ncBCOs and ncECOs are very similar type organoids that both represent cholangiocyte-like characteristics.
ncBCOs Retain Secretin Receptor Responsiveness and Increased Ion-Channel Activity in vitro Compared to cBCOs
FIGURE 4

ncBCOs retain secretin receptor responsiveness and increased ion channel activity in vitro compared to cBCOs. (A) qRT-PCR of ncBCOs and cBCOs (both, n = 6), for cholangiocyte specific channels and transporters. Showing a significant upregulation (p < 0.05, as indicated by *) for AQP1, CFTR, ASBT, NKCC-1, and GGT in ncBCOs compared to cBCOs. Error bars are displayed as SEM. (B) Representative ion-channel functionality of 2D-grown bile-cholangiocyte organoids in non-canonical Wnt-stimulated conditions (ncBCOs, line 2) and bile cholangiocyte organoids in canonical-Wnt-stimulated organoids (cBCOs, line 1) in an Ussing chamber, stimulation with cAMP-activator (forskolin), resulted in an increase in short circuit current; however, secretin stimulation (to the basolateral side) only gave a response in the ncBCOs. In similar fashion, somatostatin (basolateral addition) only give a response in ncBCOs and not in cBCOs, while CFTR inhibition via GlyH-101 (luminal addition), resulted in an inhibition of the channel in both organoid-types, indicating the presence of functional CFTR channels in both organoids, but only somatostatin and secretin receptors are functional in ncECOs. Moreover, it seems that CFTR-function is higher in organoids in non-canonical Wnt stimulating conditions compared to organoids in canonical-Wnt-stimulating conditions. (C) Heatmap and clustering based expression of cholangiocyte-related gene expression as analyzed by gene array for functional enzymes (ALPI and GGT1), channels (SLC12A2—also known as NKCC1-, SLC10A2—also known as ASBT-, AQP1, ANO1, and CFTR) and receptors (SCTR and SSTR) between cICOs (n = 3), cECOs (n = 3), and ncECO (n = 3). Color key represents the log2 transformed signal intensities after variance stabilizing normalization.
Discussion
In this study, we demonstrate that primary biliary epithelial cells (cholangiocytes) collected from bile can be cultured and expanded efficiently in vitro while retaining their cholangiocyte characteristics. We show that these ncBCOs, could be efficiently initiated from ERCP and gallbladder bile and could be cultured long-term. In addition, we show that ncBCOs have similar characteristics when compared to ncECOs as described by
Cholangiocytes organoids, either initiated from tissue or bile in both culture conditions, are most likely risen from primary cholangiocytes (
This in vitro study might validate that the use of non-canonical Wnt cell culture conditions results (for some aspects) in a more mature cholangiocyte in vitro, compared to Wnt/β-catenin-stimulated conditions. Here we show that ncBCO have higher expression of mature cholangiocyte-channel genes compared to cBCOs. In addition, gene expression as analyzed by gene-array shows that expression of the functional cholangiocyte-related genes such as ANO1, NKCC1, CFTR, GGT, AQP1, and the basolateral receptor SCTR is higher in non-canonical Wnt-stimulated cholangiocyte organoids when compared to Wnt/β-catenin cultured organoids from tissue. Moreover, ncBCOs (and ncECOs) have functionality of the typical cholangiocyte-receptors: secretin and somatostatin while cBCOs (and cICOs) do not. Interestingly, our analysis provides evidence that there is some plasticity in cholangiocyte organoids since we demonstrate that gene-expression profiles in BCOs change depending on the culture conditions. In line with our hypothesis, the functional-related genes ASBT and GGT are upregulated when culture medium is switched from canonical Wnt to non-canonical Wnt stimulating compounds. Also other genes (HNF1β and PROM1) are differently expressed after switching. Together, our results indicate that culture conditions most probably drive the expression of specific genes in cholangiocyte organoids and that cholangiocytes might be more mature under non-canonical Wnt stimulating conditions. It is important to note that ncECO were shown capable of forming functional bile duct tissue in vivo after repopulating collagen scaffolds and transplantation in mice (
In conclusion, our studies confirm and extend the studies previously reported on ncECOs (
Statements
Data availability statement
The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found below: https://www.ebi.ac.uk/arrayexpress/, E-MTAB-4591; https://www.ebi.ac.uk/arrayexpress/, E-MTAB-9044; and https://www.ebi.ac.uk/arrayexpress/, E-MTAB-9807.
Ethics statement
The studies involving human participants were reviewed and approved by the Medische Ethische Toetsings Commissie (METC), Erasmus MC. The patients/participants provided their written informed consent to participate in this study.
Author contributions
FR, MV, and LL designed the study. FR, HR, and LM acquired the data. FR, MV, and LL interpreted the data and wrote the draft of the manuscript. J-WP, GT, and JI were critical in obtaining material support. All authors provided intellectual content as well as critical revision.
Funding
This project was partially funded by the MLDS-Diagnostiek grant D16–26 of the Dutch Gastroenterology and Hepatology Fund (MLDS).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcell.2020.630492/full#supplementary-material
References
1
AizaraniN.SavianoA.Sagar, MaillyL.DurandS.HermanJ. S.et al (2019). A human liver cell atlas reveals heterogeneity and epithelial progenitors.Nature572199–204. 10.1038/s41586-019-1373-2
2
AloiaL.McKieM.VernazG.Cordero-EspinozaL.AleksievaN.van den AmeeleJ.et al (2019). Epigenetic remodelling licences adult cholangiocytes for organoid formation and liver regeneration.Nat. Cell Biol.211321–1333.
3
BarkerN.HuchM.KujalaP.van de WeteringM.SnippertH. J.van EsJ. H.et al (2010). Lgr5(+ve) stem cells drive self-renewal in the stomach and build long-lived gastric units in vitro.Cell Stem Cell625–36. 10.1016/j.stem.2009.11.013
4
BoyerJ. L. (2013). Bile formation and secretion.Compr. Physiol.31035–1078.
5
CuiS.CapecciL. M.MatthewsR. P. (2011). Disruption of planar cell polarity activity leads to developmental biliary defects.Dev. Biol.351229–241. 10.1016/j.ydbio.2010.12.041
6
CurròG.IapichinoG.MelitaG.LorenziniC.CucinottaE. (2005). Laparoscopic cholecystectomy in child-Pugh class C cirrhotic patients.JSLS9311–315.
7
DekkersJ. F.WiegerinckC. L.de JongeH. R.BronsveldI.JanssensH. M.de Winter-de GrootK. M.et al (2013). A functional CFTR assay using primary cystic fibrosis intestinal organoids.Nat. Med.19939–945. 10.1038/nm.3201
8
HuH.GehartH.ArtegianiB.LÖpez-IglesiasC.DekkersF.BasakO.et al (2018). Long-term expansion of functional mouse and human hepatocytes as 3D organoids.Cell1751591–1606. 10.1016/j.cell.2018.11.013
9
HuchM.GehartH.van BoxtelR.HamerK.BlokzijlF.VerstegenM. M.et al (2015). Long-term culture of genome-stable bipotent stem cells from adult human liver.Cell160299–312. 10.1016/j.cell.2014.11.050
10
KorcP.ShermanS. (2016). ERCP tissue sampling.Gastrointest. Endosc.84557–571. 10.1016/j.gie.2016.04.039
11
LevitskyJ. (2011). Operational tolerance: past lessons and future prospects.Liver Transpl.17222–232. 10.1002/lt.22265
12
MurrayK. F.CarithersR. L.Jr. (2005). AASLD practice guidelines: evaluation of the patient for liver transplantation.Hepatology411407–1432. 10.1002/hep.20704
13
Pepe-MooneyB. J.DillM. T.AlemanyA.AlemanyA.Ordovas-MontanesJ.MatsushitaY.et al (2019). Single-cell analysis of the liver epithelium reveals dynamic heterogeneity and an essential role for YAP in homeostasis and regeneration.Cell Stem Cell2523–38. 10.1016/j.stem.2019.04.004
14
Planas-PazL.SunT.PikiolekM.CochranN. R.BerglingS.OrsiniV.et al (2019). YAP, but Not RSPO-LGR4/5, signaling in biliary epithelial cells promotes a ductular reaction in response to liver injury.Cell Stem Cell2539–53. 10.1016/j.stem.2019.04.005
15
RimlandC. A.TilsonS. G.MorellC. M.TomazR. A.LuW. Y.AdamsS. E.et al (2020). Regional differences in human biliary tissues and corresponding in vitro derived organoids.Hepatology10.1002/hep.31252[Epub ahead of print].
16
RitchieM. E.PhipsonB.WuD.HuY.LawC. W.ShiW.et al (2015). Limma powers differential expression analyses for RNA-sequencing and microarray studies.Nucleic Acids Res.43:e47. 10.1093/nar/gkv007
17
RoestH. P.OomsL. S. S.GillisA. J. M.IJzermansJ. N. M.LooijengaL. H. J.DorssersL. C. J.et al (2019). Cell-free microRNA miR-505-3p in graft preservation fluid is an independent predictor of delayed graft function after kidney transplantation.Transplantation103329–335. 10.1097/tp.0000000000002527
18
SampaziotisF.JustinA. W.TysoeO. C.SawiakS.GodfreyE. M.UpponiS. S.et al (2017). Reconstruction of the mouse extrahepatic biliary tree using primary human extrahepatic cholangiocyte organoids.Nat. Med.23954–963.
19
SampaziotisF.SegeritzC. P.VallierL. (2015). Potential of human induced pluripotent stem cells in studies of liver disease.Hepatology62303–311. 10.1002/hep.27651
20
SatoT.StangeD. E.FerranteM.VriesR. G.Van EsJ. H.Van den BrinkS.et al (2011). Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett’s epithelium.Gastroenterology1411762–1772. 10.1053/j.gastro.2011.07.050
21
SatoT.VriesR. G.SnippertH. J.van de WeteringM.BarkerN.StangeD. E.et al (2009). Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche.Nature459262–265. 10.1038/nature07935
22
SeeffL. B.EversonG. T.MorganT. R.CurtoT. M.LeeW. M.GhanyM. G.et al (2010). Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial.Clin. Gastroenterol. Hepatol.8877–883. 10.1016/j.cgh.2010.03.025
23
SorokaC. J.AssisD. N.AlrabadiL. S.RobertsS.CusackL.JaffeA. B.et al (2019). Bile-derived organoids from patients with primary sclerosing cholangitis recapitulate their inflammatory immune profile.Hepatology70871–882. 10.1002/hep.30470
24
StrazzaboscoM.FabrisL. (2012). Development of the bile ducts: essentials for the clinical hepatologist.J. Hepatol.561159–1170. 10.1016/j.jhep.2011.09.022
25
StrömbergJ.HammarqvistF.Sadr-AzodiO.SandblomG. (2015). Cholecystectomy in patients with liver cirrhosis.Gastroenterol. Res. Pract.2015:783823.
26
TysoeO. C.JustinA. W.BreviniT.ChenS. E.MahbubaniK. T.FrankA. K.et al (2019). Isolation and propagation of primary human cholangiocyte organoids for the generation of bioengineered biliary tissue.Nat. Protoc.141884–1925. 10.1038/s41596-019-0168-0
27
VandervoortJ.SoetiknoR. M.MontesH.LichtensteinD. R.Van DamJ.RuymannF. W.et al (1999). Accuracy and complication rate of brush cytology from bile duct versus pancreatic duct.Gastrointest. Endosc.49(3 Pt 1)322–327. 10.1016/s0016-5107(99)70008-8
28
VerstegenM. M. A.RoosF. J. M.BurkaK.GehartH.JagerM.de WolfM.et al (2020). Human extrahepatic and intrahepatic cholangiocyte organoids show region-specific differentiation potential and model cystic fibrosis-related bile duct disease.Sci. Rep.10:21900.
Summary
Keywords
cholangiocytes, bile, organoids, minimal invasive, human, non-canonical Wnt
Citation
Roos FJM, Verstegen MMA, Muñoz Albarinos L, Roest HP, Poley J-W, Tetteroo GWM, IJzermans JNM and van der Laan LJW (2021) Human Bile Contains Cholangiocyte Organoid-Initiating Cells Which Expand as Functional Cholangiocytes in Non-canonical Wnt Stimulating Conditions. Front. Cell Dev. Biol. 8:630492. doi: 10.3389/fcell.2020.630492
Received
17 November 2020
Accepted
31 December 2020
Published
09 February 2021
Volume
8 - 2020
Edited by
Delilah Hendriks, Hubrecht Institute (KNAW), Netherlands
Reviewed by
Kourosh Saeb-Parsy, University of Cambridge, United Kingdom; Laura Broutier, INSERM U1052 Centre de Recherche en Cancerologie de Lyon, France
Updates

Check for updates
Copyright
© 2021 Roos, Verstegen, Muñoz Albarinos, Roest, Poley, Tetteroo, IJzermans and van der Laan.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Luc J. W. van der Laan, l.vanderlaan@erasmusmc.nl
This article was submitted to Stem Cell Research, a section of the journal Frontiers in Cell and Developmental Biology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.